Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Wealth Enhancement Advisory Services LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,311 shares of the company’s stock after selling 2,930 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in CRISPR Therapeutics were worth $1,075,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Capital International Investors lifted its holdings in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after buying an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after buying an additional 1,074,238 shares in the last quarter. Vanguard Group Inc. boosted its position in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock valued at $68,329,000 after buying an additional 10,579 shares during the last quarter. Finally, Baker BROS. Advisors LP increased its stake in shares of CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock valued at $51,483,000 after buying an additional 464,936 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 8.5%

Shares of CRSP stock opened at $41.86 on Monday. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88. The firm has a fifty day moving average of $36.83 and a 200-day moving average of $41.10. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -9.58 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the business earned ($1.43) EPS. The firm’s revenue was up 71.6% on a year-over-year basis. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CRSP shares. Morgan Stanley upped their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research report on Wednesday, February 12th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Barclays lowered their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $81.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $71.75.

Insider Activity

In related news, insider Naimish Patel sold 3,932 shares of the firm’s stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider now directly owns 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,953 shares of company stock worth $736,087 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.